Updated on 23 August 2013
Korea Ministry of Food and Drug Safety (MFDS) has approved Transcranial Magnetic Stimulation technology (TMS)
Singapore: Korea Ministry of Food and Drug Safety (MFDS) has approved Transcranial Magnetic Stimulation technology (TMS), a non-invasive, non-drug therapeutic device that delivers highly-focused magnetic pulses to stimulate and activate neurons in localized regions of the brain, developed by NeuroStar, for the treatment of major depressive disorder.
Neuronetics will work with distribution partner BR Holdings, a Seoul-based leader in medical device technology, to provide sales, marketing and clinical support as medical facilities and physicians adopt NeuroStar, which is already deployed at more than 550 installations worldwide.
"The MFDS approval of NeuroStar significantly extends Neuronetics' global leadership in addressing the need for a safe, effective, non-drug treatment for depression," said Mr Bruce Shook, CEO, Neuronetics "Our distribution partnership with BR Holdings will enable us to rapidly scale up delivery of the NeuroStar TMS system into the world's 15th largest economy, which represents a remarkable opportunity to meet the needs of millions of depression patients who need an option beyond drug therapy."